Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Amniotics AB Announces Positive Pre-clinical Proof-of-concept Results for PulmoStem™ in End-stage Lung Disease
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that PulmoStem™ significantly reduces the incidence of […]
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia
Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, announced […]
Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer
Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has […]
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered […]
Biomunex Appoints Dr. Simon Plyte, PhD, as Chief Scientific Officer
Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapies through the discovery and development of […]
CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of […]
GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company Sierra Oncology for $1.9bn
GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies […]
Cannabotech's Botanical Drug for Pancreatic Cancer Has Demonstrated Killing 100% of Cancer Cells Without Damaging the Healthy Cells in the Cell Model
Cannabotech (CNTC.TA), which is involved in the development of a botanical drug based on an extract […]
Major Journal Publishes Landmark Proteomics Study Demonstrating Development of an Unprecedented New Clinical Cardiovascular Risk Test
In one of the largest proteomic studies ever conducted and published April 6 in the […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more